Browse by ▼

Baxter International, Inc.

  • Michael Price is Bullish on This Drug Manufacturer

    By Anh HOANG - June 17, 2013 | Tickers: BAX, BDX, HSP

    In the London Value Investor Conference 2013, a famous value investor Michael Price has pitched Hospira (NYSE: HSP) to be one of his favorite stocks. As of March 2013, Michael Price owned 400,000 Hospira shares. Interestingly, Hospira seems to be a popular stock among investment gurus including Brian Rogers, John Rogers and Larry Robins. Let’s take a closer look to see whether or not we should invest in more »

  • Don’t Believe the Hype about Medical Device Stocks

    By Jonathan Yates - June 9, 2013 | Tickers: BAX, BDX, BSX

    A major loser in the Affordable Health Care Act, or Obamacare, was supposed to be the medical device and equipment industry, which ranges from blue chip heavyweights with wide product offerings such as Boston Scientific (NYSE: BSX), Becton,Dickinson & Co. (NYSE: BDX), and Baxter International (NYSE: BAX) to specialized small caps such as PLC Systems (NASDAQ: PLCSF). The main feature of Obamacare that was expected to damage the sector the more »

  • Why Baxter Is Soaring Despite Alzheimer's Disappointment

    By Piyush Arora - May 29, 2013 | Tickers: BAX, JNJ, MNTA

    Earlier this month, Baxter International (NYSE: BAX) reported that the clinical trials for the treatment of Alzheimer’s disease (Gammagard) had failed. The company also announced that it would be discontinuing its research work on Alzheimer’s, following which its shares tanked by around 5%.

    Alzheimer’s blow

    Alzheimer’s disease impacts 36 million people annually around the globe, and any breakthrough in curing the disease would have raked in more »

  • Diagnosing Alzheimer's First

    By Seth Robey - May 17, 2013 | Tickers: BAX, LLY, JNJ, PFE

    Alzheimer's is a debilitating neurodegenerative disorder affecting approximately 5 million Americans, yet its causes are remarkably enigmatic.  Nonetheless, pharma and biotech companies continually throw money at potential blockbusters that lack innovative scientific forethought and inevitably fail to meet primary endpoints in clinical trials.  Their gamble is over a piece of the $203 billion pie that the Alzheimer's Association estimates as a 2013 cost of care (rising to an more »

  • Insights From CI Investments’ Five Big Buys

    By Aubrey Tabuga - May 16, 2013 | Tickers: ABBV, BAX, CVX, C, OXY

    CI Investments has recently won seven 2013 Lipper Fund Awards for its strong risk-adjusted returns relative to its peers. I looked into its first quarter big buys from a fundamental lens to provide investment insights. These are AbbVie (NYSE: ABBV), Baxter (NYSE: BAX), Chevron (NYSE: CVX), Occidental Petroleum (NYSE: OXY), and Citigroup (NYSE: C).

    Interestingly, these stocks have all posted positive earnings surprises, have P/E ratios not higher than more »

  • The Best In An Expensive Sector

    By Matthew Frankel - May 13, 2013 | Tickers: BAX, BDX, MDT

    Medtronic Inc. (NYSE: MDT) is one of the leading manufacturers of equipment for the health care industry.  In fact, the company has a leading market share in several categories, including pacemakers, defibrillators, and diabetes products just to name a few.  The company has grown its revenues tremendously over the past decade (see below), with sales up each and every year, including the entire tumultuous 2008-2010 period.  How many other health more »

  • Collecting Dividends From the Healthcare Sector

    By Ash Anderson - April 27, 2013 | Tickers: BAX, PFE, DGX

    Continuing on with the dividend trend that my recent articles have been focusing upon, I’d like to now take a look at some solid healthcare companies. These companies must meet two strict criteria in that they must be profitable, and they must pay a dividend. That’s not too harsh, right? Well, away we go into the wild world of healthcare!

    Major drug manufacturers

    You had to guess that more »

  • Buy This Healthcare Outperformer

    By Piyush Arora - April 19, 2013 | Tickers: BAX, BDX, BCR

    The healthcare industry is known to have a stable topline and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26%, respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think the healthcare industry is still ripe for value more »

  • Will Dividend Growth for This Dividend King Start Slowing?

    By Michael Weber - April 18, 2013 | Tickers: BAX, CAH, JNJ, TEVA

    Johnson & Johnson (NYSE: JNJ) has been considered a dividend growth star for a number of years now. They have increased their dividend for 50 consecutive years and currently sport an impressive 5 and 10 year dividend growth rate of 8.2% and 11.6%. 

    With these types of dividend growth rates and such a long dividend streak it is easy to see why Johnson & Johnson is considered a favorite among more »

  • Buy This Healthcare Outperformer

    By Piyush Arora - April 6, 2013 | Tickers: BAX, BDX, BCR

    The healthcare industry is known to have a stable topline and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26%, respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think the healthcare industry is still ripe for value more »

  • Buy This Healthcare Outperformer

    By Piyush Arora - April 6, 2013 | Tickers: BAX, BDX, BCR

    The healthcare industry is known to have a stable topline and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26%, respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think the healthcare industry is still ripe for value more »

  • An Outperformer in Healthcare

    By Piyush Arora - April 3, 2013 | Tickers: BAX, BDX, BCR

    Healthcare industry is known to have a stable topline and steady rewards and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26% respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think Healthcare industry is still ripe for more »

  • Ted Weschler's Favorite Health Care Company

    By Ted Cooper - March 14, 2013 | Tickers: BAX, DVA, FMS

    The growing obesity epidemic is putting a strain on the U.S. health care system. But not everyone loses from this trend. Dialysis providers DaVita HealthCare Partners (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) are poised to profit from the proliferation of obesity and related diseases, namely diabetes.

    Profitable Niche

    Once you look at the business, it is not hard to understand why Ted Weschler -- one of two managers more »

  • Johnson & Johnson (JNJ): Will Dividend Growth For This Dividend King Start Slowing?

    By Michael Weber - March 11, 2013 | Tickers: BAX, CAH, JNJ, TEVA

    Johnson & Johnson (JNJ) has been considered a dividend growth star for a number of years now. They have increased their dividend for 50 consecutive years. They currently sport an impressive 5 and 10 year dividend growth rate of 8.2% and 11.6%. 

    With these types of dividend growth rates and such a long dividend streak it is easy to see why Johnson & Johnson is considered a favorite among dividend more »

  • Reasons To Buy These Healthcare Stocks

    By David Gould - March 8, 2013 | Tickers: BAX, MDT, STJ

    If you are looking to diversify into the healthcare sector with lower downside, the medical device industry could be the one for you. This slice of the sector is more predictable than pharmaceutical producers, since the products tend to have a more clear cut science before any dollars are put into R&D. Below, I review two leaders in this field, Baxter and Medtronic.

    Baxter (NYSE: BAX)

    Baxter is a more »

  • Tweedy Browne's Top Stocks (Last Part)

    By Anh HOANG - March 6, 2013 | Tickers: BAX, PM

    Tweedy Browne, one of the most respected value investment funds in the world, was featured in the article “The Superinvestors of Graham-and-Doddsville,” written by Warren Buffett in 1984. As its investment philosophy derives from Benjamin Graham, value investors should follow Tweedy Browne’s moves closely.

    In two previous articles, I have talked about its four biggest holdings: Johnson & Johnson, Cisco Systems, Devon Energy and ConocoPhillips. In this article, I will more »

  • America is Aging and These Stocks Will Benefit Handsomely

    By Robert Ciura - February 25, 2013 | Tickers: BAX, BSX, MDT

    It’s plainly evident that the United States is an aging society.  Baby Boomers are nearing retirement age in huge numbers.  According to the Department of Health and Human Service’s Administration of Aging (AoA), the older population--persons 65 years or older--numbered 39.6 million in 2009 (the latest year for which data is available). They represented 12.9% of the U.S. population, about one in every eight Americans more »

  • A Value Play in Healthcare

    By Piyush Arora - February 23, 2013 | Tickers: BAX, BDX, BCR

    According to various sources, around 78.3 million babies were born in the US, between 1946 and 1964 i.e. post World War 2. People of this generation are often referred as baby boomers, the era is remembered as the baby boom. Today, those babies have grown up and are aged between 49 and 67 years. It’s a well-known fact that the elderly have greater health concerns, and those more »

  • A Look at 2 Leading Medical Device Stocks

    By David Gould - February 18, 2013 | Tickers: BAX, MDT, STJ

    Medical device companies face significant opportunities from targeting the retiring baby boomer generation. Device innovations in blood disorders and heart conditions have gotten a large focus, but the foray into drug development has caught many analysts by surprise. Will this pay dividends? And what other strategies are they taking to hedge against domestic headwinds? Below, I present my take on Baxter and Medtronic.

    Baxter (NYSE: BAX)

    Baxter is a leading more »

  • Patent Cliff a Welcome Event for This Pharma Giant

    By Ted Cooper - February 15, 2013 | Tickers: BAX, HSP, TEVA

    While most pharmaceutical companies dreaded the patent cliff, one company welcomed it. Teva Pharmaceutical Industries  (NYSE: TEVA) is the world's largest integrated pharmaceutical manufacturer. While it does extensive R&D to discover new and innovative drugs, the most stable aspect of the business comes from its generic drugs business. The generic business is getting a large boost from the current spate of patent expirations -- it can now manufacture generic more »

  • Page 1 of 3